BLUE * Stock Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
bluebird bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$16.24 |
52 Week High | US$60.50 |
52 Week Low | US$15.90 |
Beta | 0.80 |
1 Month Change | -29.39% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -97.22% |
5 Year Change | n/a |
Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Shareholder Returns
BLUE * | MX Biotechs | MX Market | |
---|---|---|---|
7D | -21.7% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how BLUE * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how BLUE * performed against the MX Market.
Price Volatility
BLUE * volatility | |
---|---|
BLUE * Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: BLUE *'s share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BLUE *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 323 | Andrew Obenshain | www.bluebirdbio.com |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
BLUE * fundamental statistics | |
---|---|
Market cap | Mex$2.96b |
Earnings (TTM) | -Mex$1.55b |
Revenue (TTM) | Mex$369.92m |
8.0x
P/S Ratio-1.9x
P/E RatioIs BLUE * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BLUE * income statement (TTM) | |
---|---|
Revenue | US$21.73m |
Cost of Revenue | US$255.71m |
Gross Profit | -US$233.98m |
Other Expenses | -US$142.81m |
Earnings | -US$91.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.47 |
Gross Margin | -1,076.97% |
Net Profit Margin | -419.62% |
Debt/Equity Ratio | 0% |
How did BLUE * perform over the long term?
See historical performance and comparison